A double-blind, placebo-controlled, parallel study to evaluate the effects of GW856553 on endothelial function/vascular compliance in subjects with dyslipidaemia.
Latest Information Update: 28 Jun 2023
Price :
$35 *
At a glance
- Drugs Losmapimod (Primary)
- Indications Dyslipidaemias; Lipid metabolism disorders
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 15 Oct 2008 Actual start date changed from May 2007 to July 2007 as reported by Clinicaltrials.gov.
- 12 Oct 2008 Trial phase changed from I/II to II as reported by ClinicalTrials.gov.
- 23 Jan 2008 The expected completion date for this trial is now 1 Feb 2008.